Results 121 to 130 of about 5,951 (176)

Exploring Tafamidis Effects Through PBPK-QSP Modelling. [PDF]

Pharmaceutics
Ulaszek S, Lisowski B, Wiśniowska B, Polak S.   +3 more
europepmc   +1 more source

Bridging the life-course exposome approach with a life-cycle perspective in safe and sustainable by design (SSbD) for chemical risk. [PDF]

Hum Genomics
Sarigiannis D, Nikiforou F, Karakoltzidis A, Papaioannou N, Karakitsios S.   +4 more
europepmc   +1 more source

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework. [PDF]

CPT Pharmacometrics Syst Pharmacol
Pellowe M, Dubbelboer I, Sjögren E.
europepmc   +1 more source

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics-Based Biomarkers. [PDF]

Clin Transl Sci
Prasad B.
europepmc   +1 more source

Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approach. [PDF]

Front Tuberc
Park H, Singh A, Srivastava A, Thalluri B, Mathieu CJ, Gupta P, Pearce CM, Zohaib Ali M, Alshiraihi IM, Maloney Norcross SE, Hickey AJ, Gonzalez-Juarrero M, Meibohm B.   +12 more
europepmc   +1 more source

Utility of a physiologically-based pharmacokinetic model for investigating time-dependent variability in the fetal-to-maternal plasma concentration ratio of digoxin. [PDF]

J Pharmacokinet Pharmacodyn
Okuba K, Ikeda K.
europepmc   +1 more source

Assessing transporter-mediated rifampin-linezolid interaction using physiologically-based pharmacokinetic modelling. [PDF]

Br J Clin Pharmacol
Nguyen HD, Pham VH, Hoglund RM, Tarning J, Ding J.   +4 more
europepmc   +1 more source

PBPK in liver cirrhosis population

, 2019
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

QSARs for PBPK modelling of environmental contaminants

SAR and QSAR in Environmental Research, 2011
Physiologically-based pharmacokinetic (PBPK) models are increasingly finding use in risk assessment applications of data-rich compounds. However, it is a challenge to determine the chemical-specific parameters for these models, particularly in time- and resource-limiting situations.
T, Peyret, K, Krishnan
exaly   +3 more sources

PBPK in Preterm and Term Neonates: A Review

Current Pharmaceutical Design, 2018
The neonatal population remains one of the populations in which appropriate dosing regimens are still lacking, resulting in a large off-label or unlicensed use. Clinical research in these small infants remains a challenge, which sparks the need for modeling and simulation as an additional tool for neonatal drug research.The use of physiologically based
An Vermeulen, Jan Van Bocxlaer, Robin Michelet   +2 more
exaly   +3 more sources